MSD (Switzerland)

Recent papers from MSD (Switzerland)

1. The clinical benefits of immediate versus delayed use of PCSK9 inhibitors for patients with established atherosclerotic cardiovascular disease in the UKEuropean Heart Journal · 2026
2. The independent association of mortality with LDL-C management, and number and types of atherosclerotic cardiovascular disease events: a large nationwide real-world cohort studyEuropean Heart Journal · 2026
3. Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18–64 years in Switzerland using PCV21Journal of Medical Economics · 2026
4. Benefit-Risk Balance for Medicinal Products: Report Summary from the Council for International Organizations of Medical Sciences (CIOMS) Working Group XIIClinical Therapeutics · 2026
5. From Joint Clinical Assessment to National Decisions: EU HTA Implementation and Implications for Patient AccessJournal of Market Access & Health Policy · 2026
6. Spatial proteomic analysis in human Alzheimer’s disease brains enables identification of microenvironment-dependent microglial cell statesNature Neuroscience · 2026
7. The health and economic burden of invasive pneumococcal diseases attributable to PCV21 or PCV20 serotypes among adults aged ≥18 years in SwitzerlandVaccine X · 2026
8. Economic burden of pulmonary arterial hypertension in Switzerland.2026
9. Quantifying public and private investment in biopharmaceutical R&D: a study of seven middle- and high-income countriesSHILAP Revista de lepidopterología · 2026
10. Public Health Impact and Cost-Effectiveness of 2-Dose vs 1-Dose Human Papillomavirus Vaccination Regimen in Saudi ArabiaJournal of health economics and outcomes research · 2026
11. Consideration of the limitations of cost-effectiveness analysis for severe-rare disease drugs and potential solutions: a structured literature reviewHealth Economics Review · 2026
12. Extrapolation of Time-to-Event Survival Outcomes of Histology-Independent Therapies Using a Bayesian Hierarchical ModelMedical Decision Making · 2026
13. Knowledge, Attitudes, and Behaviors Toward Human Papillomavirus Vaccination Among Adults in SwitzerlandJAMA Network Open · 2026
14. Assessing the burden of HPV-associated cancers in Brazil: Hospitalization and mortality trends from 2011 to 2019Human Vaccines & Immunotherapeutics · 2026
15. Delta price cost-effectiveness analysis of PCV21 vs PCV20 use in adults aged ≥65 years in SwitzerlandJournal of Medical Economics · 2026
16. Abstract PS3-09-26: Real-world clinical characteristics, treatment patterns and outcomes among UK and French patients with early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer treated with neoadjuvant chemotherapyClinical Cancer Research · 2026
17. Abstract PS3-09-05: Real-world clinical characteristics and treatment patterns among UK and French patients with a recent diagnosis (2020 onwards) of early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (ER+/HER2-eBC)Clinical Cancer Research · 2026
18. Discrete Choice Experiment (DCE) as a Tool to Elicit Patient Preferences in a Complex Benefit–Risk Evaluation: A Case StudyClinical Drug Investigation · 2026
19. Serotype-specific incidence and comparative vaccine coverage of invasive pneumococcal disease among adults ≥65 years of age in European countries from 2011 to 2023Vaccine · 2026
20. An observational study to identify selection criteria for initiation of different first line treatment options in patients with non-small cell lung cancerCancer Treatment and Research Communications · 2026